The Compound
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence — derived from a protein found in human gastric juice. First characterized by researchers at the University of Zagreb in the 1990s, it has since accumulated one of the most extensive preclinical research portfolios of any synthetic peptide.
The compound is not FDA-approved for any human indication. It has no completed Phase 3 clinical trials. And as of May 2026, it exists in a regulatory gray zone — recently removed from the FDA's Category 2 restricted compounding list, with a formal Pharmacy Compounding Advisory Committee review scheduled for July 23, 2026. What follows is a factual overview of what the published research shows.
Tissue Repair and Tendon Healing
Tendon research is where BPC-157's preclinical data is most dense. Multiple rodent studies using the Achilles tendon model have documented accelerated tendon fiber organization, increased collagen type I deposition, and measurable upregulation of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) at injury sites. These findings have been replicated across several independent research groups.
The mechanism appears to center on angiogenesis — the formation of new blood vessels at injury sites — and growth factor signaling. In damaged tendons, BPC-157 administration consistently correlates with increased blood vessel density and improved biomechanical strength relative to controls. Dosing in rodent models typically ranges from 2 to 10 mcg/kg administered intraperitoneally or subcutaneously.
Gastrointestinal Research
Given its derivation from gastric proteins, GI research has been a primary focus. Published studies document protective and healing effects in rodent models of gastric ulcers, inflammatory bowel disease analogs, and NSAID-induced intestinal damage. BPC-157 has demonstrated dose-dependent gastroprotection in multiple ulcer models, accelerated healing of colonic anastomoses (surgical reconnections), and reduction of inflammatory markers in IBD-analog models.
The GI data is notable for its consistency across different damage models and dosing routes, including both injectable and oral administration — a rare finding for a peptide compound, as most peptides are degraded in the GI tract before reaching systemic circulation.
Other Preclinical Domains
Published animal studies extend beyond tendons and gut. Researchers have investigated BPC-157 in models of muscle injury, bone healing, nerve damage, liver protection, and even neurological function. A 2026 review in the International Journal of Molecular Sciences characterized the compound as supporting "angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways." The breadth of tissue types studied is unusual for a single peptide.
Human Data: Limited but Emerging
As of early 2026, no large-scale randomized controlled trials in humans have been completed. However, BPC-157 has advanced through early-phase human safety evaluations. A Phase 2 trial conducted at the University of Zagreb evaluated subcutaneous BPC-157 at 250 mcg twice daily for rotator cuff tendinopathy in 48 patients over 12 weeks. Published results reported a 38% reduction in pain scores and a 29% improvement in shoulder range of motion compared to placebo, with no serious adverse events.
This represents the most rigorous human efficacy data published to date. It's encouraging but far from definitive — 48 patients over 12 weeks is a pilot study, not a validation trial.
Safety Profile
In published rodent studies, BPC-157 has demonstrated a favorable safety profile with no reported lethal dose (LD50) established — researchers have been unable to identify a toxic dose in animal models. The Zagreb Phase 2 trial reported no serious adverse events. However, the absence of large-scale human safety data means the long-term risk profile in humans remains uncharacterized.
Regulatory Status (May 2026)
BPC-157 was placed on the FDA's Category 2 restricted compounding list in September 2023, meaning licensed compounding pharmacies could not legally prepare it. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides would be reclassified. The companies that nominated BPC-157 for the restricted list subsequently withdrew their nominations, and the compound came off Category 2 effective April 23, 2026.
The FDA's Pharmacy Compounding Advisory Committee will formally review BPC-157 on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list — which would allow licensed compounding pharmacies to legally prepare it under physician prescription. This review is not an FDA drug approval process; it addresses compounding eligibility only.
Bottom Line
BPC-157 has the deepest preclinical evidence base of any research peptide in the tissue-repair space. The data is unusually consistent across tissue types and study groups. But the translation gap from rodent models to proven human therapeutics remains wide, and the regulatory landscape is evolving in real time. The July 2026 PCAC meeting will be the next major inflection point.